​

SELLAS Life Sciences Group (SLS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SLS Stock Forecast

SELLAS Life Sciences Group stock forecast is as follows: an average price target of $2.80 (represents a 215.32% upside from SLS’s last price of $0.89) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

SLS Price Target

The average price target for SELLAS Life Sciences Group (SLS) is $2.80 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $3.20 to $2.40. This represents a potential 215.32% upside from SLS's last price of $0.89.

SLS Analyst Ratings

Buy

According to 2 Wall Street analysts, SELLAS Life Sciences Group's rating consensus is 'Buy'. The analyst rating breakdown for SLS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

SELLAS Life Sciences Group Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2022Industrial Alliance Securities$3.20$0.89259.55%260.36%
Jun 28, 2022Cantor Fitzgerald$2.40$0.93158.06%170.27%

The latest SELLAS Life Sciences Group stock forecast, released on Nov 15, 2022 by Industrial Alliance Securities company, set a price target of $3.20, which represents a 259.55% increase from the stock price at the time of the forecast ($0.89), and a 260.36% increase from SLS last price ($0.89).

SELLAS Life Sciences Group Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.89$0.89$0.89
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of SELLAS Life Sciences Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to SELLAS Life Sciences Group's last price of $0.89. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2022Alliance Global PartnersBuyBuyHold
Jun 28, 2022Cantor FitzgeraldOverweightOverweightHold

SELLAS Life Sciences Group's last stock rating was published by Alliance Global Partners on Nov 15, 2022. The company gave SLS a "Buy" rating, the same as its previous rate.

SELLAS Life Sciences Group Financial Forecast

SELLAS Life Sciences Group Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Mar 21Mar 15Mar 14
Revenue---------$5.70M$2.75M$2.17M
Avg Forecast-------$13.00M$13.00M$7.22M$2.97M$7.46M
High Forecast-------$13.00M$13.00M$8.66M$3.57M$8.95M
Low Forecast-------$13.00M$13.00M$5.78M$2.38M$5.97M
# Analysts-------31121513
Surprise %---------0.79%0.92%0.29%

SELLAS Life Sciences Group's average Quarter revenue forecast for Sep 23 based on 1 analysts is $13.00M, with a low forecast of $13.00M, and a high forecast of $13.00M. SLS's average Quarter revenue forecast represents a 128.07% increase compared to the company's last Quarter revenue of $5.70M (Mar 21).

SELLAS Life Sciences Group EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Mar 21Mar 15Mar 14
# Analysts-------31121513
EBITDA--------$94.00K$-2.40M$-10.03M$-1.99M
Avg Forecast-------$-2.60M$-2.60M$-3.04M$-10.78M$-3.06M
High Forecast-------$-2.60M$-2.60M$-2.44M$-8.63M$-2.45M
Low Forecast-------$-2.60M$-2.60M$-3.65M$-12.94M$-3.67M
Surprise %---------0.04%0.79%0.93%0.65%

3 analysts predict SLS's average Quarter EBITDA for Dec 23 to be $-2.60M, with a high of $-2.60M and a low of $-2.60M. This is -2865.96% lower than SELLAS Life Sciences Group's previous annual EBITDA (Sep 23) of $94.00K.

SELLAS Life Sciences Group Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Mar 21Mar 15Mar 14
# Analysts-------31121513
Net Income--------$-9.27M$-2.40M$-10.54M$-2.54M
Avg Forecast$-7.17M$-7.51M$-7.51M$-7.85M$-7.28M$-8.65M$-9.99M$5.92M$1.19M$-3.04M$-11.33M$-3.90M
High Forecast$-7.17M$-7.51M$-7.51M$-7.51M$-6.14M$-8.65M$-9.99M$5.92M$1.21M$-2.44M$-9.06M$-3.12M
Low Forecast$-7.17M$-7.51M$-7.51M$-8.19M$-8.19M$-8.65M$-9.99M$5.92M$1.18M$-3.65M$-13.59M$-4.68M
Surprise %---------7.76%0.79%0.93%0.65%

SELLAS Life Sciences Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SLS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

SELLAS Life Sciences Group SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Mar 21Mar 15Mar 14
# Analysts-------31121513
SG&A--------$3.55M$3.56M$7.57M$6.92M
Avg Forecast-------$54.92M$54.92M$4.51M$12.56M$31.51M
High Forecast-------$54.92M$54.92M$5.41M$15.07M$37.82M
Low Forecast-------$54.92M$54.92M$3.61M$10.05M$25.21M
Surprise %--------0.06%0.79%0.60%0.22%

SELLAS Life Sciences Group's average Quarter SG&A projection for Dec 23 is $54.92M, based on 3 Wall Street analysts, with a range of $54.92M to $54.92M. The forecast indicates a 1447.99% rise compared to SLS last annual SG&A of $3.55M (Sep 23).

SELLAS Life Sciences Group EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Mar 21Mar 15Mar 14
# Analysts-------31121513
EPS--------$-0.00$-0.16$-2.40K$-600.01
Avg Forecast$-0.10$-0.11$-0.11$-0.12$-0.11$-0.13$-0.17$0.09$0.02$-0.18$-1.86$-3.17K
High Forecast$-0.10$-0.11$-0.11$-0.11$-0.09$-0.13$-0.17$0.09$0.02$-0.18$-1.49$-2.54K
Low Forecast$-0.10$-0.11$-0.11$-0.12$-0.12$-0.13$-0.17$0.09$0.02$-0.18$-2.23$-3.81K
Surprise %---------0.02%0.89%1290.34%0.19%

According to undefined Wall Street analysts, SELLAS Life Sciences Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SLS previous annual EPS of $NaN (undefined).

SELLAS Life Sciences Group Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ELEVElevation Oncology$0.67$9.001243.28%Buy
RVPHReviva Pharmaceuticals$1.40$10.00614.29%Buy
ANVSAnnovis Bio$5.11$25.50399.02%Buy
ZURAZura Bio$2.51$10.00298.41%Buy
NLSPNLS Pharmaceutics$1.85$6.00224.32%Buy
SLSSELLAS Life Sciences Group$0.88$2.80218.18%Buy
IMMXImmix Biopharma$2.29$7.00205.68%Buy
EYPTEyePoint Pharmaceuticals$8.02$22.00174.31%Buy
MREOMereo BioPharma Group$3.40$8.00135.29%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
AXSMAxsome Therapeutics$93.51$133.0042.23%Buy
MCRBSeres Therapeutics$0.88$1.2542.05%Buy
KODKodiak Sciences$8.87$11.0024.01%Buy

SLS Forecast FAQ

Is SELLAS Life Sciences Group a good buy?

Yes, according to 2 Wall Street analysts, SELLAS Life Sciences Group (SLS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of SLS's total ratings.

What is SLS's price target?

SELLAS Life Sciences Group (SLS) average price target is $2.8 with a range of $2.4 to $3.2, implying a 215.32% from its last price of $0.888. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will SELLAS Life Sciences Group stock go up soon?

According to Wall Street analysts' prediction for SLS stock, the company can go up by 215.32% (from the last price of $0.888 to the average price target of $2.8), up by 260.36% based on the highest stock price target, and up by 170.27% based on the lowest stock price target.

Can SELLAS Life Sciences Group stock reach $1?

SLS's average twelve months analyst stock price target of $2.8 supports the claim that SELLAS Life Sciences Group can reach $1 in the near future.

What are SELLAS Life Sciences Group's analysts' financial forecasts?

SELLAS Life Sciences Group's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-25.915M (high $-24.778M, low $-26.825M), average SG&A $0 (high $0, low $0), and average EPS is $-0.407 (high $-0.39, low $-0.42). SLS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.032M (high $-29.69M, low $-30.373M), average SG&A $0 (high $0, low $0), and average EPS is $-0.44 (high $-0.435, low $-0.445).

Did the SLS's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Mar 2021), SELLAS Life Sciences Group's revenue was $5.7M, missing the average analysts' forecast of $7.22M by -21.05%. The company's EBITDA was $-2.403M, missing the average prediction of $-3.044M by -21.05%. SELLAS Life Sciences Group's net income was $-2.403M, missing the average estimation of $-3.044M by -21.05%. The company's SG&A was $3.56M, missing the average forecast of $4.51M by -21.05%. Lastly, the company's EPS was $-0.16, missing the average prediction of $-0.18 by -11.11%